GlaxoSmithKline partnership acknowledges revision of ING112276

GlaxoSmithKline joint venture Shionogi-GlaxoSmithKline has announced that a protocol revision for ING112276, a clinical study for S/GSK1349572, will take place jointly with the European AIDS Treatment Group and the AIDS Treatment Activists Coalition.

The ING112276 study is a dose-ranging examination of the investigational integrase inhibitor S/GSK1349572 in antiretroviral therapy-naive patients.

As part of the revision, patients the minmium allowable CD4+ cell count will be increased to 200 cells/mm or higher, where necessary.

Dr Garrett Nichols, co-project leader for the clinical development of S/GSK1349572 at Shionogi-GlaxoSmithKline said: “Working together, we are able to draw upon the collective expertise of the HIV community, patients, clinicians, researchers and regulatory agencies to develop new medicines for the treatment of people living with HIV and AIDS.”

The Shionogi-GlaxoSmithKline venture was founded in 2001 for the commercialisation and development of new HIV and neurological disorder-fighting agents.